- MGC Pharmaceuticals (MXC) has commenced its phase two clinical trial on patients diagnosed with COVID-19
- The study is evaluating the safety and efficacy of ArtemiC — MGC’s natural, immune-modulation formula
- The trial includes a total of 50 patients at the Nazareth Hospital EMMS and Hillel Yaffe Hospital in Israel.
- The trial is expected to be completed in September and results could be available as early as the following month
- MGC Pharma will use the study data to prepare for future trials and discuss the commercial supply and sale of ArtemiC
- Company shares are trading flat at 2.7 cents each
MGC Pharmaceuticals (MXC) has commenced its phase two clinical trial on patients diagnosed with COVID-19.
The phase two double-blind, placebo-controlled clinical trial is aimed at evaluating the safety and efficacy of ArtemiC, MGC’s natural, immune-modulation formulation, in patients who have tested COVID-19 positive.
ArtemiC is made up of Artemisinin, a drug from a fern-like plant and is used against malaria, and Curcumin, which is a chemical that aids in anti-inflammatory and antioxidants.
It is then mixed with Vitamin C and Boswellia serrata, which is a herbal extract used to treat inflammatory illnesses.
The trial will include a total of 50 patients at the Nazareth Hospital EMMS and
Hillel Yaffe Hospital in Israel.
On April 17, the ‘seed to medicine’ company announced receiving approvals for this trial from the two Israel-based hospitals.
“This is a very exciting milestone for the company and the trial, and we look forward to updating our shareholders on results as they come to hand,” Co-founder and Managing Director Roby Zomer said.
The trial will be conducted over 14 days per patient and is expected to conclude recruitment in September, with results available the following month.
The results from the trial will provide data points for future trials and will help to facilitate discussions about the potential supply and sale of the ArtemiC product.
Company shares are trading flat at 2.7 cents each at 11:26 am AEST.